CEL-SCI shares are trading higher after the company announced it received FDA approval for its confirmatory study of Multikine for the treatment of head & neck cancer.
Portfolio Pulse from Benzinga Newsdesk
CEL-SCI Corporation's stock price increased following the announcement of FDA approval for its confirmatory study of Multikine in treating head & neck cancer.
May 08, 2024 | 3:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CEL-SCI Corporation's shares rose after announcing FDA approval for a confirmatory study of its Multikine treatment for head & neck cancer.
The FDA approval for CEL-SCI's confirmatory study of Multikine directly impacts the company's prospects by potentially accelerating the development and commercialization of its treatment for head & neck cancer. This regulatory milestone is a significant positive development for the company, likely leading to increased investor confidence and a higher stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100